Freenome maps path forward for blood-based cancer screenings with $270M C round 

Freenome’s $270 million series C will fuel the company’s push to move its multiomics cancer screening technology beyond colorectal cancer.

New investor Bain Capital Life Sciences and existing investor Perceptive Advisors led the untranched round, which brings Freenome’s total private funding to more than $500 million. The round will carry Freenome through a pivotal trial of its colorectal cancer test and support the development of additional diagnostics, CEO Gabe Otte told BioCentury (see “Investors in Freenome’s Series C”)...